Key points are not available for this paper at this time.
INTRODUCTION : The introduction and broad use of new immunosuppressive agents, including biologic agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease IBD in recent decades. With such immunosuppression, the potential for opportunistic infection is a key safety concern. ...
Kucharzik et al. (Sat,) studied this question.